Business Description
Monopar Therapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US61023L1089
Description
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of?Validive?for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin?for the treatment?of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.82 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -2.5 | |||||
| 3-Year EPS without NRI Growth Rate | -1 | |||||
| 3-Year FCF Growth Rate | -10.1 | |||||
| 3-Year Book Growth Rate | -35.1 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 38.34 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 77.22 | |||||
| 9-Day RSI | 70.91 | |||||
| 14-Day RSI | 67.67 | |||||
| 3-1 Month Momentum % | 398.19 | |||||
| 6-1 Month Momentum % | 320.65 | |||||
| 12-1 Month Momentum % | 1079.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.41 | |||||
| Quick Ratio | 5.41 | |||||
| Cash Ratio | 5.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -9.2 | |||||
| Shareholder Yield % | -2.76 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -105.4 | |||||
| ROA % | -84.96 | |||||
| ROIC % | -27996 | |||||
| 3-Year ROIIC % | 4073.68 | |||||
| ROC (Joel Greenblatt) % | -27996 | |||||
| ROCE % | -113.94 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 18.13 | |||||
| Price-to-Tangible-Book | 18.13 | |||||
| EV-to-EBIT | -17.25 | |||||
| EV-to-EBITDA | -17.25 | |||||
| EV-to-FCF | -20.28 | |||||
| Price-to-Net-Current-Asset-Value | 18.13 | |||||
| Price-to-Net-Cash | 18.26 | |||||
| Earnings Yield (Greenblatt) % | -5.8 | |||||
| FCF Yield % | -4.44 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MNPR
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Monopar Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.99 | ||
| Beta | 1.55 | ||
| 3-Year Sharpe Ratio | 0.52 | ||
| 3-Year Sortino Ratio | 1.56 | ||
| Volatility % | 244.75 | ||
| 14-Day RSI | 67.67 | ||
| 14-Day ATR ($) | 2.341228 | ||
| 20-Day SMA ($) | 21.39 | ||
| 12-1 Month Momentum % | 1079.75 | ||
| 52-Week Range ($) | 1.545 - 38.5 | ||
| Shares Outstanding (Mil) | 5.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Monopar Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Monopar Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Monopar Therapeutics Inc Frequently Asked Questions
What is Monopar Therapeutics Inc(MNPR)'s stock price today?
The current price of MNPR is $25.38. The 52 week high of MNPR is $38.50 and 52 week low is $1.55.
When is next earnings date of Monopar Therapeutics Inc(MNPR)?
The next earnings date of Monopar Therapeutics Inc(MNPR) is 2025-03-28 Est..
Does Monopar Therapeutics Inc(MNPR) pay dividends? If so, how much?
Monopar Therapeutics Inc(MNPR) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers